S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)
Free CHMA Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$3.76
▼
$3.76
50-Day Range
$3.76
▼
$4.71
52-Week Range
$2.77
▼
$5.74
Volume
147 shs
Average Volume
2.12 million shs
Market Capitalization
$217.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CHMA stock logo

About Chiasma Stock (NASDAQ:CHMA)

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

CHMA Stock News Headlines

October 29, 2023 | thestreet.com
Chiasma Craters on FDA Drug Rejection
October 6, 2022 | globenewswire.com
Orphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswire
April 19, 2024 | DTI (Ad)
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
September 28, 2022 | businesswire.com
Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business Wire
September 16, 2022 | marketscreener.com
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.com
September 16, 2022 | streetinsider.com
Amryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.com
September 7, 2022 | uk.finance.yahoo.com
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UK
August 12, 2022 | gurufocus.com
MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com
April 19, 2024 | DTI (Ad)
Start loving Mondays like this
Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!
August 4, 2022 | globenewswire.com
Amryt Reports Record Q2 2022 Results - GlobeNewswire
July 12, 2022 | businesswire.com
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business Wire
July 12, 2022 | finance.yahoo.com
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo Finance
June 20, 2022 | finance.yahoo.com
Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo Finance
June 18, 2022 | gurufocus.com
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.com
June 16, 2022 | finance.yahoo.com
At 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo Finance
June 15, 2022 | globenewswire.com
The oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswire
June 15, 2022 | finance.yahoo.com
The oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo Finance
June 8, 2022 | finance.yahoo.com
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo Finance
May 13, 2022 | gurufocus.com
Top 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.com
May 6, 2022 | financialpost.com
Amryt Reports Record Q1 2022 Results - Financial Post
May 4, 2022 | globenewswire.com
Amryt Reports Record Q1 2022 Results - GlobeNewswire
May 4, 2022 | stockhouse.com
2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - Stockhouse
March 21, 2022 | benzinga.com
Insights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - Benzinga
March 16, 2022 | globenewswire.com
Global Oral Proteins and Peptides Market to 2032 - by - GlobeNewswire
March 11, 2022 | streetinsider.com
Amryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.com
March 9, 2022 | globenewswire.com
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswire
February 28, 2022 | prnewswire.com
Warm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswire
See More Headlines
Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2021
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CHMA
CUSIP
N/A
CIK
1339469
Web
www.chiasmapharma.com
Phone
617-928-5300
Fax
N/A
Employees
85
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,780,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-113.57%
Return on Assets
-57.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.91
Quick Ratio
7.08

Sales & Book Value

Annual Sales
$1.11 million
Price / Sales
196.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
57,894,000
Free Float
N/A
Market Cap
$217.68 million
Optionable
Not Optionable
Beta
1.28
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 56)
    Pres, CEO & Director
    Comp: $827.55k
  • Mr. Anand Varadan (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $542.27k
  • Mr. John Brendan Doyle (Age 44)
    Sr. VP, CFO & Treasurer
  • Mr. Drew Enamait (Age 47)
    VP of Fin. & Admin.
  • Ms. Dawn Schottlandt CFA
    VP of Investor Relations & Corp. Communications
  • Mr. Lee G. Giguere (Age 40)
    VP, Gen. Counsel and Sec.
  • Mr. Derek Brown
    VP of Marketing
  • Mr. Joe Lyons
    Exec. Director of HR
  • Dr. William H. Ludlam (Age 55)
    Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. David M. Schubert
    Sr. VP of Regulatory & Quality

Key Competitors

View All Competitors

CHMA Stock Analysis - Frequently Asked Questions

How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to the consensus estimate of $1.80 million.

What other stocks do shareholders of Chiasma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).

When did Chiasma IPO?

Chiasma (CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

This page (NASDAQ:CHMA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Urgent alert: open this for a huge profit potential
Timothy Sykes
My biggest AI fear
Paradigm Press
Man Who Predicted 2008: “This Will be Worse.”
Altimetry